BioMarin Pharmaceutical (BMRN) Expected to Post Earnings on Monday

Key Points

• BioMarin is expected to report Q3 2026 results after Monday’s market close, with analysts forecasting $1.35 in earnings per share and $1.02 billion in revenue. The company’s FY 2026 EPS guidance is $4.90–$5.10.
• In its latest quarter, BioMarin reported $1.20 EPS and $989.71 million in revenue, beating analyst estimates, while revenue increased 20% year over year.
• Analyst sentiment remains positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $88.87, well above its recent price of $54.68.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect BioMarin Pharmaceutical to announce earnings of $1.35 per share and revenue of $1.02 billion for the quarter. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Parties can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, October 26, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same period in the prior year, the company earned $1.44 earnings per share. The firm's revenue was up 20.0% on a year-over-year basis. On average, analysts expect BioMarin Pharmaceutical to post $4.10 EPS for the current fiscal year and $5.21 EPS for the next fiscal year.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $54.68 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $70.98. The stock's 50 day simple moving average is $63.01 and its two-hundred day simple moving average is $58.68. The company has a market cap of $10.58 billion, a price-to-earnings ratio of 147.78, a PEG ratio of 0.38 and a beta of 0.22.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BMRN. Jefferies Financial Group increased their target price on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a "buy" rating in a research report on Monday, August 31st. UBS Group began coverage on shares of BioMarin Pharmaceutical in a research report on Thursday. They issued a "buy" rating and a $88.00 price target on the stock. Morgan Stanley upped their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Finally, Raymond James Financial upgraded shares of BioMarin Pharmaceutical from an "outperform" rating to a "strong-buy" rating and set a $109.00 price objective for the company in a research report on Monday, October 12th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $88.87.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.